Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 18;137(11):1436-1437.
doi: 10.1182/blood.2020009968.

Sorting biologic subtypes of primary CNS lymphoma

Affiliations
Comment

Sorting biologic subtypes of primary CNS lymphoma

Mark Roschewski et al. Blood. .

Abstract

In this issue of Blood, Gandhi et al studied 91 cases of primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) (PCNSL) and compared the biologic features of tumors associated with Epstein-Barr virus (EBV) to tumors that are EBV using digital gene expression signatures and customized hybrid-capture targeted sequencing panels.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Primary CNS lymphoma can be subdivided into EBV and EBV-associated subtypes based on unique genetic alterations, gene expression signatures, and functional and microenvironmental differences. These biologic differences suggest that potential therapeutic strategies should be tailored within subtypes. ABC, activated B cell; amp, amplifications; BCR, B-cell receptor; BTK, Bruton tyrosine kinase; CAR T, chimeric antigen receptor T cell; del, deletions; IMiD, immunomodulatory imide drug; My-T-BCR, MYD88-TLR9-BCR supercomplex; mut, mutation; PI3K, phosphoinositide 3-kinase.

Comment on

References

    1. Gandhi MK, Hoang T, Law SC, et al. . EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021;137(11):1468-1477. - PMC - PubMed
    1. Young RM, Phelan JD, Shaffer AL, et al. . Taming the heterogeneity of aggressive lymphomas for precision therapy. Ann Rev Cancer Biol. 2019;3:429-455.
    1. Alizadeh AA, Eisen MB, Davis RE, et al. . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. - PubMed
    1. Schmitz R, Wright GW, Huang DW, et al. . Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407. - PMC - PubMed
    1. Chapuy B, Stewart C, Dunford AJ, et al. . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292]. Nat Med. 2018;24(5):679-690. - PMC - PubMed

Substances